Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2025-10-06 Major Shareholding Noti…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a notification of a change in major shareholding (flaggningsmeddelande) for Hansa Biopharma AB, where Polar Capital has crossed a 5% threshold. This is a standard regulatory disclosure regarding significant ownership changes, which fits the definition of a Major Shareholding Notification.
2025-10-06 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a formal notification of a change in major shareholding (flaggningsmeddelande) submitted to the Swedish Financial Supervisory Authority (Finansinspektionen). It details the transaction by Redmile Group, LLC in Hansa Biopharma AB, specifically noting that their aggregate percentage of total votes and shares has fallen below the 20% threshold. This fits the definition of a Major Shareholding Notification (MRQ).
2025-10-03 Swedish
Hansa Biopharma publishes disclosure document for admission to trading of shares on Nasdaq Stockholm
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing the publication of a disclosure document for the admission of newly issued shares to trading on Nasdaq Stockholm. It describes a directed share issue and the subsequent filing of a disclosure document with the Swedish Financial Supervisory Authority. Per the 'Menu vs Meal' rule, this is an announcement regarding a report/document rather than the report itself, and it specifically relates to the issuance and listing of shares, making it a Share Issue/Capital Change announcement.
2025-10-02 English
Hansa Biopharma publicerar informationsdokument för upptagande till handel av aktier på Nasdaq Stockholm
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Hansa Biopharma announcing the publication of an information document regarding the admission to trading of newly issued shares on Nasdaq Stockholm. It explicitly states that the information document has been registered with the Swedish Financial Supervisory Authority and is available on the company's website. Following the 'Menu vs Meal' rule, this document is an announcement of a report/document rather than the report itself, making it a Report Publication Announcement (RPA).
2025-10-02 Swedish
Hansa Biopharma has carried out a directed share issue of 17 million shares, raising proceeds of approximately USD 71 million
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Hansa Biopharma announcing a 'directed share issue' of 17 million shares to raise capital. It details the subscription price, the book-building process, the use of proceeds, and the impact on share capital and dilution. This falls squarely under the definition of a 'Share Issue/Capital Change' (SHA) announcement, as it describes the issuance of new shares and the resulting change in capital structure.
2025-10-02 English
Hansa Biopharma har genomfört en riktad emission av 17 miljoner aktier, vilket tillför bolaget cirka 71 miljoner USD
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Hansa Biopharma announcing the completion of a directed share issue (private placement) of 17 million shares to institutional investors. It details the subscription price, the rationale for the capital raise, the use of proceeds, and the impact on the company's share capital and dilution. This falls under the category of share issuance and capital changes.
2025-10-02 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.